, Tracking Stock Market Picks
Enter Symbol:
Rating: CLVS
Neutral $35
down 67.00 %

Clovis Oncology Inc (NASDAQ: CLVS) downgraded to Neutral with price target $35 by Mizuho

Monday,  Nov 16, 2015  1:25 PM ET by Lynn Gilbert

Mizuho downgraded Clovis Oncology Inc (NASDAQ: CLVS) to Neutral with price target $35. Previously, Mizuho rated Clovis Oncology Inc (NASDAQ: CLVS) to Buy with price
target $103 on 06/01/2015, when the stock price was valued at $84.41. Since then, Clovis Oncology Inc's stock price has lost 67% as of 11/16/2015's recent price of $27.71.
If you had followed Mizuho's previous recommendation on CLVS, you would have lost 67% of your investment in 168 days.

Clovis Oncology, Inc. (Clovis) is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy